A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

This study is testing a combination of two drugs — azacitidine (a chemotherapy that reactivates silenced genes) and pembrolizumab (an immune checkpoint inhibitor that helps the immune system attack cancer) — for people with Hodgkin's lymphoma that has returned or stopped responding to previous treatments. **You may be eligible if...** - You have relapsed or progressive Hodgkin's lymphoma and are not a candidate for high-dose chemotherapy - You are at least 1 year old (this study includes both pediatric and adult patients) - Your organ function and performance status are adequate (ECOG ≤3 or Lansky ≥50 for pediatric) - You have received prior treatments and are willing to use contraception if applicable **You may NOT be eligible if...** - You are allergic to azacitidine or pembrolizumab - You have uncontrolled infection, hypertension, or heart failure - You have HIV or active Hepatitis B or C - You have an active autoimmune disease (e.g., inflammatory bowel disease, Wegener's syndrome) - You have recently received a live vaccine (within 30 days) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.